Halozyme Therapeutics Inc. buy Benchmark Co.
Start price
20.10.23
/
50%
€33.23
Target price
20.10.24
€47.17
Performance (%)
26.30%
Price
05.06.24
€41.97
Summary
This prediction is currently active. The prediction currently has a performance of 26.30%. This prediction currently runs until 20.10.24. The prediction end date can be changed by Benchmark_Co_ at any time. Benchmark_Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Halozyme Therapeutics Inc. | 6.038% | 6.038% |
iShares Core DAX® | 0.597% | 3.083% |
iShares Nasdaq 100 | 0.899% | 5.338% |
iShares Nikkei 225® | 1.775% | -1.206% |
iShares S&P 500 | 0.990% | 3.500% |
Comments by Benchmark_Co_ for this prediction
In the thread Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Stopped prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€36.23
16.04.24
16.04.24
€46.98
16.04.25
16.04.25
13.41%
05.06.24
05.06.24
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€31.35
19.01.24
19.01.24
€45.94
19.01.25
19.01.25
33.88%
05.06.24
05.06.24